Key Takeaways
- Fasenra (benralizumab) is a biologic therapy approved for severe eosinophilic asthma in adults and children 12 and older.
- It is delivered as a subcutaneous injection at an infusion clinic, every four weeks for the first three doses and every eight weeks after that.
- Asthma that requires frequent rescue inhaler use, oral steroid bursts, or hospital visits may not be fully controlled, and a biologic conversation may be in order.
- Prepare for the appointment with a clear symptom history, a list of triggers, and questions about how Fasenra fits into your overall care plan.
- Smart Infusion Therapy Services administers Fasenra and other asthma biologics in Wisconsin, and patients can talk to their provider about a referral.
How to Approach the Fasenra Conversation With Your Doctor
The short answer: if your severe asthma is not fully controlled by standard inhaler therapy and your eosinophil counts are elevated, Fasenra may be worth a conversation with your allergist or pulmonologist. The most productive appointment is one where you arrive prepared, with a clear sense of your symptom pattern, your treatment history, and the questions that matter most to you.
Asthma affects more than 25 million people in the United States, according to the American Lung Association, and a meaningful share continue to have symptoms despite using inhalers and other standard therapies. For those patients, biologic medications like Fasenra may offer a more targeted way to address underlying inflammation.
Signs Your Asthma May Not Be Fully Controlled
Many patients live with more symptoms than they realize. Common signs that asthma may not be fully controlled include:
- Using a rescue inhaler more than twice a week (outside of pre-exercise use)
- Waking at night because of asthma symptoms
- Needing an oral steroid burst more than once or twice a year
- Limiting activities because of breathing concerns
- Visiting urgent care or the emergency room for asthma symptoms
If several of these sound familiar, it is reasonable to ask your provider whether your current treatment plan is doing enough.
How Fasenra Works for Severe Eosinophilic Asthma
Fasenra (benralizumab) is a monoclonal antibody that targets the interleukin-5 receptor on eosinophils, a type of white blood cell that often drives airway inflammation in severe asthma. By depleting eosinophils, Fasenra may help reduce the underlying inflammation that contributes to flares and persistent symptoms.
For patients whose eosinophil counts are elevated and whose asthma is not well controlled on standard inhalers, the American Academy of Allergy, Asthma & Immunology notes that biologic therapies have become an important option as part of a step-up treatment plan.
Because severe asthma can be driven by different inflammatory pathways, an allergist or pulmonologist may compare Fasenra with other biologics, such as Tezspire (tezepelumab) and Nucala (mepolizumab), before recommending the option best suited to a patient's profile.
What to Bring to Your Appointment
A well-prepared visit makes for a more useful conversation. Before your appointment, gather:
- A symptom diary: Note how often you use your rescue inhaler, any nighttime symptoms, and the impact on daily activities.
- A trigger list: Allergies, exercise, weather, smoke, pet exposure, and infections all matter.
- A treatment history: Which inhalers and other medications you have tried, how well each worked, and any side effects.
- Recent test results: Pulmonary function tests, eosinophil counts, and any allergy testing.
- Hospital and ER visits: Dates and reasons over the past one to two years.
This information helps your provider decide whether a biologic like Fasenra fits your situation.
Questions to Ask Your Doctor About Fasenra
Bring these questions to your visit:
- Am I a candidate for biologic therapy, and what eosinophil count level supports that?
- How does Fasenra compare with other asthma biologics for my specific situation?
- What results have other patients seen, and how soon might I notice changes?
- What are the most common Fasenra side effects?
- How often would I need treatments, and where would they be given?
- How is Fasenra covered by my insurance, and what financial support is available?
- What happens if Fasenra does not work for me?
A clear set of questions helps the conversation move beyond a general explanation and into the specifics of your care.
What to Expect if Your Doctor Recommends Biologic Therapy
Fasenra is given as a 30 mg subcutaneous injection. The initial dosing schedule is one injection every four weeks for the first three doses, then one injection every eight weeks. Treatment is typically delivered at an outpatient infusion clinic rather than at home, so a trained nurse can administer the dose and monitor for any immediate reactions.
For patients in Wisconsin, Smart Infusion Therapy Services offers Fasenra administration in a private, comfortable outpatient setting. The clinic team typically:
- Verifies insurance coverage and helps with prior authorization
- Schedules visits at predictable times to fit your routine
- Administers the injection in a private treatment area
- Monitors briefly after each dose
- Communicates with your referring allergist or pulmonologist about response and any concerns
Many patients find this kind of outpatient experience easier to plan around than a hospital infusion suite, with shorter visits and a calmer setting.
How Smart Infusion Supports Personalized Asthma Care
Severe asthma looks different from one patient to the next. Smart Infusion's immunology infusion programs include Fasenra and other biologics, and the team works closely with referring allergists and pulmonologists to keep treatment aligned with each patient's specific plan. The smaller clinic setting often means more time per appointment for questions and patient education.
Talk to Your Provider About a Referral to Smart Infusion
If your asthma symptoms are interrupting daily life despite standard inhaler therapy, a conversation about biologics is worth having. With the right preparation, you can leave that appointment with a clear next step.
If Fasenra is part of your treatment plan, talk to your provider about a referral to Smart Infusion Therapy Services for biologic administration close to home.
Frequently Asked Questions
Who is Fasenra recommended for?
Fasenra is approved as an add-on maintenance therapy for adults and children 12 and older with severe eosinophilic asthma that is not well controlled by standard inhaler-based treatment. Your allergist or pulmonologist can confirm whether your asthma profile and eosinophil counts make you a candidate.
What are the most common Fasenra side effects?
The most commonly reported Fasenra side effects in clinical studies include headache and sore throat. Some patients may experience injection-site reactions or, less commonly, hypersensitivity reactions. Your care team will review all potential risks before starting treatment.
Is Fasenra an infusion or an injection?
Fasenra is a subcutaneous injection, not an IV infusion. It is typically administered at an outpatient infusion clinic so that a trained nurse can deliver the dose and monitor for any immediate reactions.
How is Fasenra different from other biologic treatments for asthma?
Fasenra and several other asthma biologics target inflammation in different ways. Fasenra directly depletes eosinophils through the IL-5 receptor. Nucala (mepolizumab) also targets IL-5 but binds the cytokine itself rather than its receptor. Tezspire (tezepelumab) works further upstream by blocking TSLP, while other biologics target IgE or IL-4 and IL-13 pathways. The right choice depends on your specific asthma profile, biomarker results, and treatment history, and an allergist or pulmonologist typically reviews several options before recommending one.
